The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
01-Jun-10
$109 million
Target:
AT&T Japan (an AT&T Inc. company)
Acquiror:
Internet Initiative Japan
Advised AT&T Inc., a premier communications holding company, on its sale of the domestic network outsourcing business of AT&T Japan, its Japanese enterprise unit, to Internet Initiative Japan, one of Japan's leading Internet-access and comprehensive network solutions providers
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
18-Jul-05
$101 million
Target:
TeleCity Plc
Acquiror:
Inhoco 3236 plc (joint venture between 3i and Oak Hill Capital)
Advised TeleCity plc on the recommended offer by 3i and Oak Hill Capital
10-Sep-18
$100 million
Target:
Montserrat Day Hospital Group
Acquiror:
Primary Health Care
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
30-Dec-21
$100 million
Target:
Photonics Division of Intevac
Acquiror:
EOTech LLC
Advised Intevac, a leading developer of thin-film processing systems for the electronics market and high-sensitivity digital sensors for the defense industry, on the sale of its Photonics division to EOTech, a manufacturer of holographic sighting systems and accessories for military and commercial customers
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
28-Jul-16
$80 million
Target:
BioD, LLC
Acquiror:
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
24-Oct-18
$41 million
Target:
TeePublic
Acquiror:
Redbubble
Advised Redbubble, a global online independent artist community and marketplace, on the acquisition of TeePublic, a similar online platform, and associated A$61 million equity raising
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
17-Dec-19
~$35 million
Target:
Sye business area of Net Insight AB
Acquiror:
Amazon.com, Inc.
Advised Net Insight AB, a global leader in media networks, on the sale of Sye, a market-leading true live “over-the-top” (OTT) technology for low-latency live streaming, to Amazon.com, Inc.
07-May-21
N/A
Target:
MindPath Care Centers
Acquiror:
Community Psychiatry
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US
01-Jun-21
Undisclosed
Target:
VEP Healthcare
Acquiror:
U.S. Acute Care Solutions
Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions
15-Jun-18
$NA
Target:
MIPS Tech
Acquiror:
Wave Computing
Advised Wave Computing, an artificial intelligence solutions company developing proprietary dataflow-based architecture systems, on the acquisition of MIPS Tech, a leading provider of processor architecture IP, and other strategic initiatives
09-Sep-21
Undisclosed
Target:
Quicken
Acquiror:
Aquiline Capital Partners
Advised Aquiline Capital Partners on its acquisition of Quicken, the best-selling personal finance software in the U.S., from H.I.G. Capital
23-Feb-10
$NA
Target:
Heartscape Technologies, Inc.
Acquiror:
Roper Industries, Inc.
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company
11-Aug-14
$NA
Target:
MannKind Corporation
Acquiror:
Sanofi
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
20-Sep-21
Undisclosed
Target:
Faes Farma, flagship product Bilastine
Acquiror:
Hikma Specialty USA INC
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
10-Aug-06
$NA
Target:
Forest City Ratner
Acquiror:
Forest City Enterprises Inc.
Advised Forest City Enterprises, Inc. on the restructuring of its business relationship with its New York City affiliate Forest City Ratner
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
01-Feb-22
Undisclosed
Target:
Alteon Health
Acquiror:
U.S. Acute Care Solutions
Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions
06-Oct-09
$263 milllion
Target:
ICT Group
Acquiror:
Sykes Enterprises
Advised ICT Group on its merger with Sykes Enterprises, both leading global providers of outsourced customer contact management solutions and services
21-Feb-14
$NA
Target:
BancTec, Inc.
Acquiror:
HandsOn3, LLC
Advised BancTec, Inc., a leading business process outsourcing company, on its acquisition by HandsOn3, LLC and subsequent combination with Dataforce Group to create one of the largest pure-play BPO businesses, spanning over 50 countries
26-Oct-21
Undisclosed
Target:
Oculii Corporation
Acquiror:
Ambarella, Inc.
Advised Ambarella, Inc., an AI vision silicon company, on the acquisition of Oculii Corporation, a leading developer of AI software designed to enhance radar perception